Armata Pharmaceuticals, Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

ARMP$3.75-1.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)


· · Three Months Ended · · Nine Months Ended
· · September 30, · · September 30,
· 2025 · 2024 · 2025 · 2024
Grant and award revenue	$1,159	$2,973	$3,819	$3,939
Operating expenses
Research and development	5,824	9,485	17,647	25,975
General and administrative	3,111	3,244	8,983	9,861
Total operating expenses	8,935	12,729	26,630	35,836
Operating loss	(7,776)	(9,756)	(22,811)	(31,897)
Other income (expense)
Interest income	90	294	257	567
Interest expense	(4,346)	(2,923)	(11,756)	(7,462)
Change in fair value of the Convertible Loan	(14,643)	6,904	(15,191)	17,276
Total other income (expense), net	(18,899)	4,275	(26,690)	10,381
Net loss	$(26,675)	$(5,481)	$(49,501)	$(21,516)
Per share information:
Net loss per share, basic and diluted	$(0.74)	$(0.15)	$(1.37)	$(0.60)
Weighted average shares outstanding, basic and diluted	36,226,285	36,180,124	36,201,674	36,153,388

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.